Patent US2634620A successfully refreshed from Google Patents.
Patent US6329501B1 successfully refreshed from Google Patents.
US6329501B1
Expired / Lapsed
US
⏱️ 0.0 years remaining
Methods and compositions for targeting compounds to muscle
Assignee: Auburn University
•
Filing: 1998-05-26
•
Granted: 2001-12-11
•
Expires: 2018-05-26
Abstract
Abstract Compositions for use in targeting therapies to muscle cells are provided. The compositions comprise peptides which are capable of binding muscle cells in vivo.
Inventors
- 👤 Bruce F. Smith
- 👤 Tatiana Samoilova
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-05 22:30
CPC Classifications
C; C07; C07K; C07K7/00; C07K7/04; C07K7/06; A; A61; A61K; A61K47/00; A61K47/50; A61K47/51; A61K47/62; A61K48/00; C07K14/00; C07K14/435; C07K14/46; C07K14/47; C07K14/4701; C07K14/4707; C07K14/4708; C07K14/4716; C12; C12N; C12N15/00; C12N15/09; C12N15/87; G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/68; G01N33/6887; A61K38/00; G01N2800/00; G01N2800/28; G01N2800/2878; G01N2800/2885
Claims Analysis
Total Claims: 8
Claim 1
Independent Claim
142 words
An isolated peptide, wherein said peptide is 7 amino acids to 20 amino acids, comprising an amino acid sequence selected from the group consisting of: SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, and SEQ ID NO: 29.
Claim 2
Dependent Claim
142 words
An isolated peptide, wherein said peptide is 7 amino acids to 20 amino acids, comprising an amino acid sequence selected from the group consisting of: SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, and SEQ ID NO: 29.
Claim 3
Dependent Claim
17 words
The peptide of claim 1 , wherein said peptide is capable of binding muscle cells in vivo.
Claim 4
Dependent Claim
14 words
The peptide of claim 2 , wherein said peptide is a muscle-type specific peptide.
Claim 5
Dependent Claim
134 words
The peptide of claim 3 , said muscle-type specific peptide comprising an amino acid sequence selected from the group consisting of: SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, and SEQ ID NO: 28.
Claim 6
Dependent Claim
28 words
The peptide of claim 3 , wherein said peptide is capable of binding specific muscle cells selected from the group consisting of smooth, skeletal, and cardiac muscle cells.
Claim 7
Dependent Claim
14 words
The peptide of claim 3 , wherein said peptide is a species specific peptide.
Claim 8
Dependent Claim
14 words
The peptide of claim 3 , wherein said peptide is a species independent peptide.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2004-12-10 | 2005-06-11 | 2005-12-11 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2008-12-10 | 2009-06-11 | 2009-12-11 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2012-12-10 | 2013-06-11 | 2013-12-11 | $7700.00 | Window Closed / Lapsed |